Additionally, Kuur shareholders are eligible to receive up to $115 million of milestone payments.
Kuur is a clinical-stage biotech company focused on developing off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies.
Johnson Lau, Chief Executive Officer of Athenex, said: "We are excited to add Kuur Therapeutics and its innovative allogeneic CAR-NKT technology to the Athenex platform. Kuur's innovative technology, combined with our TCR program, could propel us into a leadership position in cell therapy."
Price Action: ATNX shares are up 45.5% at $5.4 during the premarket session on the last check Wednesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.